title: VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
abstract: Functional VIP/PACAP receptors were identified in the human glioblastoma cell line T98G, based on the relative potency of VIP, PACAP and PACAP-38 to stimulate adenylate cyclase activity. Analysis of the T98G cells mRNA by reverse transcription followed by a polymerase chain reaction (RT-PCR) demonstrated the expression of the mRNA coding for the VIP2 receptor subclass only. VIP, PACAP-27 and PACAP-38 were potent and efficIent inhibitors of cell proliferation, assessed by the colorimetric MTT assay. VIP, PACAP-27 and PACAP-38 also reduced the incorporation of 3H-thymidine in T98G cells, but did not significantly alter the percentage of cells present at each stage of the cell cycle. Thus, VIP and PACAP, probably acting through a VIP2 receptor subtype, decreased cell proliferation.
authors.affiliation: Laboratoire de Chimie Biologique et de la Nutrition, Université Libre de Bruxelles, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Vertongen
authors.forename: I
authors.initials: I
authors.lastname: Camby
authors.forename: F
authors.initials: F
authors.lastname: Darro
authors.forename: R
authors.initials: R
authors.lastname: Kiss
authors.forename: P
authors.initials: P
authors.lastname: Robberecht
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism*; D001932:Brain Neoplasms / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004789:Enzyme Activation / Q000187:drug effects; D005909:Glioblastoma / Q000473:pathology*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D009363:Neoplasm Proteins / Q000187:drug effects* / Q000502:physiology; D009479:Neuropeptides / Q000494:pharmacology*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000096:biosynthesis; D018005:Receptors, Vasoactive Intestinal Peptide / Q000187:drug effects* / Q000502:physiology; D051239:Receptors, Vasoactive Intestinal Peptide, Type II; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
chemical_list: C495401:ADCYAP1 protein, human; D004273:DNA, Neoplasm; D006131:Growth Inhibitors; D009363:Neoplasm Proteins; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012333:RNA, Messenger; D018005:Receptors, Vasoactive Intestinal Peptide; D051239:Receptors, Vasoactive Intestinal Peptide, Type II; D014660:Vasoactive Intestinal Peptide; D000262:Adenylyl Cyclases